Home » Stocks » ZYME

Zymeworks Inc. (ZYME)

Stock Price: $30.38 USD 0.20 (0.66%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 1.40B
Revenue (ttm) 38.95M
Net Income (ttm) -180.55M
Shares Out 46.16M
EPS (ttm) -3.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $30.38
Previous Close $30.18
Change ($) 0.20
Change (%) 0.66%
Day's Open 30.37
Day's Range 29.29 - 30.57
Day's Volume 234,327
52-Week Range 27.64 - 59.03

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will pre...

4 days ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT™, and Zanidatamab Mechanisms of Action at AACR Annual Meeting

1 week ago - Business Wire

With the trading day about halfway over, the broad markets largely were pushing higher, except for the Dow Jones industrial average.

Other stocks mentioned: BB, LRCX, SHOP, ZM, BHP, DCPH, SQ
2 weeks ago - 24/7 Wall Street

The clinical-stage antibody treatment developer has a fair way to go before it gets a product to market -- but it's not going it alone.

3 weeks ago - The Motley Fool

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the acceptance of five a...

1 month ago - Business Wire

VANCOUVER, Canada--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the year ende...

1 month ago - Business Wire

Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that management will par...

2 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that James Priour, forme...

2 months ago - Business Wire

The company announced early data for an experimental cancer drug that disappointed investors.

2 months ago - The Motley Fool

Zymeworks said a third of patients responded to a high dose of its cancer treatment — and ZYME stock crashed to a four-month low Thursday. Shares hit their lowest point since September.

2 months ago - Investors Business Daily

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that the Company has beg...

2 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced new and updated clinical...

3 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishment...

3 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will pre...

3 months ago - Business Wire

Investors need to pay close attention to Zymeworks (ZYME) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

ZYME has a set of 3 drug discovery/development platforms which have generated major deals from big pharma. Its self-owned asset ZW25 is inching closer towards registrational stage.

4 months ago - Seeking Alpha

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the selection of three a...

4 months ago - Business Wire

ALAMEDA, Calif., SOUTH SAN FRANCISCO, Calif. & VANCOUVER, British Columbia--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL), Iconic Therapeutics, Inc. (Iconic) and Zymeworks Inc. (NYSE:ZYME) today announ...

Other stocks mentioned: EXEL
4 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that its partner, BeiGene...

4 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the U.S. Food and D...

4 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the European Commiss...

4 months ago - Business Wire

VANCOUVER, British Columbia & BURLINGAME, Calif.--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and ALX Oncology Ho...

5 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will part...

5 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the...

5 months ago - Business Wire

The opportunity is vast for Ontrak, Nano-X Imaging, and Zymeworks.

Other stocks mentioned: NNOX, OTRK
6 months ago - The Motley Fool

VICTORIA, BC, Sept. 17, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD.

7 months ago - PRNewsWire

Zymeworks (ZYME) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

8 months ago - Zacks Investment Research

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 26.74% and 44.72%, respectively, for the quarter ended June 2020.

8 months ago - Zacks Investment Research

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the...

8 months ago - Business Wire

Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

8 months ago - Zacks Investment Research

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today hosted a webcast and conference ca...

9 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it and longtime par...

9 months ago - Business Wire

Zymeworks (ZYME) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

Zymeworks Inc. (ZYME) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

10 months ago - Zacks Investment Research

Zymeworks Inc (ZYME) delivered earnings and revenue surprises of 28.89% and 6.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

11 months ago - Zacks Investment Research

These three developmental-stage pharma stocks are attracting some of the smartest investors right now.

Other stocks mentioned: AUPH, KOD
1 year ago - The Motley Fool

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -97.62% and -79.64%, respectively, for the quarter ended December 2019.

1 year ago - Zacks Investment Research

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

These developers of drugs for cancer, neurological conditions, and rare diseases may boost risk-taking investors' portfolios.

Other stocks mentioned: AUPH, XENE
1 year ago - The Motley Fool

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -1.45% and 1.22%, respectively, for the quarter ended September 2019.

1 year ago - Zacks Investment Research

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

With Breast Cancer Awareness Month drawing to a close and the San Antonio Breast Cancer Symposium on the horizon, stay alert for breaking news from companies developing new treatments.

Other stocks mentioned: MGNX, MRUS, SGEN
1 year ago - The Motley Fool

Canadian biotech Zymeworks Inc. (NYSE: ZYME) over the weekend announced more data from an ongoing clinical trial of a drug to treat HER2-type cancers and announced a Phase 2 trial in another cancer drug...

1 year ago - Benzinga

Doctors, researchers, and pharmaceutical experts will converge upon Barcelona to share the latest results in cancer research. Here is a run-down on three to watch.

Other stocks mentioned: AMGN, IMMU
1 year ago - The Motley Fool

Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Zymeworks.

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor Zymeworks.

1 year ago - Zacks Investment Research

Shares have nearly doubled since my initial recommendation to buy the dip in February of last year.

1 year ago - Seeking Alpha

About ZYME

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HE... [Read more...]

Industry
Biotechnology
IPO Date
Apr 28, 2017
CEO
Ali Tehrani
Employees
352
Stock Exchange
NYSE
Ticker Symbol
ZYME
Full Company Profile

Financial Performance

In 2020, Zymeworks's revenue was $38.95 million, an increase of 31.84% compared to the previous year's $29.54 million. Losses were -$180.55 million, 24.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for Zymeworks stock is "Strong Buy." The 12-month stock price forecast is 56.50, which is an increase of 85.98% from the latest price.

Price Target
$56.50
(85.98% upside)
Analyst Consensus: Strong Buy